Polyethylene glycol safety in children
聚乙二醇对儿童的安全性
基本信息
- 批准号:8892324
- 负责人:
- 金额:$ 32.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-10 至 2019-09-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Project Summary/Abstract
PEG 3350 is polymeric medicine that is commonly used to treat constipation and for colon cleansing prior to
colonoscopy. Although PEG 3350 is only approved by the U.S. FDA for use in people ≥17 years of age for no
more than seven days, this medicine is very commonly used in young children, often at adult doses, for months
or years at a time. The safety of PEG 3350 use by children or for prolonged periods is not known.
Furthermore, although PEG 3350 is a polymer that is poorly absorbed, batches of this medicine tested by the
FDA have been found to contain small amounts of low molecular weight compounds (e.g. ethylene glycol and
diethylene glycol) that might be absorbed and are known to be toxic in high enough doses. Finally, some
families who have given PEG 3350 to their children have reported symptoms to the FDA that they are
concerned may have been caused by PEG 3350 ingestion. In particular, there is a concern that PEG 3350
components might cause neurobehavioral symptoms. To address the potential toxicity of PEG 3350 in children
(in response RFA-FD-14-088) we plan to develop exceptionally sensitive assays for PEG 3350 components
and metabolites thought to be potentially toxic, enroll children, collect biospecimens, collect detailed linked
clinical and behavioral data, and analyze serum specimens. Specifically, we will collect serum from children
who take PEG 3350 to treat constipation, but who do not have underlying bowel problems or neurobehavioral
problems. We will also collect serum from children who have bowel problems that might predispose to
increased PEG 3350 component absorption or who have underlying neurological or neurobehavioral problems
that might make them more sensitive to PEG 3350 components. We will also collect neurobehavioral data and
clinical history for each child, and stool and urine from a subset of children. In addition, we will enroll children
who are not taking PEG 3350 in case unexpected metabolites are detected in biospecimens from children who
are taking PEG 3350. Sample analysis will be performed using state-of-the-art equipment in the Metabolic
Disease Laboratory at our institution, the Children’s Hospital of Philadelphia. As a large pediatric
gastroenterology group we have recommended PEG 3350 to many children since this medicine was first
approved by the FDA for adult use and we are very interested in working with the FDA to assess the safety of
this medicine in children.
项目摘要/摘要
聚乙二醇3350是一种聚合物药物,通常用于治疗便秘和结肠清洁。
结肠镜检查。尽管PEG3350只被美国食品和药物管理局批准用于17岁以下的人≥,但没有
在七天多的时间里,这种药物通常在幼儿中使用,通常是成人剂量,持续数月
或者一次几年。儿童使用或长时间使用PEG3350的安全性尚不清楚。
此外,尽管聚乙二醇3350是一种吸收能力很差的聚合物,但这种药物的批次经过了
FDA已被发现含有少量的低分子化合物(如乙二醇和
二甘醇),可能会被吸收,已知在足够高的剂量下是有毒的。最后,一些
给孩子服用PEG3350的家庭向FDA报告了他们的症状
可能是由于摄入了聚乙二醇3350而引起的。尤其令人担忧的是,PEG3350
这些成分可能会导致神经行为症状。为了解决聚乙二醇3350对儿童的潜在毒性
(作为回应RFA-FD-14-088)我们计划开发对PEG3350组分的异常灵敏的分析方法
和被认为有潜在毒性的代谢物,招募儿童,收集生物杀虫剂,收集详细的链接
临床和行为数据,并分析血清标本。具体来说,我们将收集儿童的血清
服用聚乙二醇3350治疗便秘,但没有潜在的肠道问题或神经行为
有问题。我们还将收集有肠道问题的儿童的血清,这些儿童可能容易患上
聚乙二醇3350成分吸收增加或有潜在神经或神经行为问题的人
这可能会使它们对聚乙二醇3350成分更加敏感。我们还将收集神经行为数据和
每个儿童的临床病史,以及部分儿童的大便和尿液。此外,我们还将招收儿童
他们没有服用PEG3350,以防在来自以下儿童的生物标本中检测到意外的代谢物
正在服用聚乙二醇3350。样品分析将使用最先进的设备在新陈代谢
疾病实验室在我们的机构,费城儿童医院。作为一名大型儿科医生
胃肠病组自PEG3350问世以来,我们一直向许多儿童推荐这种药物
已获FDA批准用于成人使用,我们非常有兴趣与FDA合作评估
这种药是儿童用的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT O HEUCKEROTH其他文献
ROBERT O HEUCKEROTH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT O HEUCKEROTH', 18)}}的其他基金
Defining non-genetic mechanisms that prevent death in a Hirschsprung disease mouse model
定义预防先天性巨结肠症小鼠模型死亡的非遗传机制
- 批准号:
10624957 - 财政年份:2021
- 资助金额:
$ 32.5万 - 项目类别:
Defining non-genetic mechanisms that prevent death in a Hirschsprung disease mouse model
定义预防先天性巨结肠症小鼠模型死亡的非遗传机制
- 批准号:
10277960 - 财政年份:2021
- 资助金额:
$ 32.5万 - 项目类别:
Biochemical and cellular mechanisms linking actin mutations to visceral myopathy
将肌动蛋白突变与内脏肌病联系起来的生化和细胞机制
- 批准号:
10363282 - 财政年份:2021
- 资助金额:
$ 32.5万 - 项目类别:
Biochemical and cellular mechanisms linking actin mutations to visceral myopathy
将肌动蛋白突变与内脏肌病联系起来的生化和细胞机制
- 批准号:
10491143 - 财政年份:2021
- 资助金额:
$ 32.5万 - 项目类别:
Defining non-genetic mechanisms that prevent death in a Hirschsprung disease mouse model
定义预防先天性巨结肠症小鼠模型死亡的非遗传机制
- 批准号:
10475689 - 财政年份:2021
- 资助金额:
$ 32.5万 - 项目类别:
VITAMIN A DEFICIENCY AND INTESTINAL MOTILITY DISORDERS
维生素 A 缺乏和肠蠕动障碍
- 批准号:
8045490 - 财政年份:2010
- 资助金额:
$ 32.5万 - 项目类别:
VITAMIN A DEFICIENCY AND INTESTINAL MOTILITY DISORDERS
维生素 A 缺乏和肠蠕动障碍
- 批准号:
8776018 - 财政年份:2010
- 资助金额:
$ 32.5万 - 项目类别:
VITAMIN A DEFICIENCY AND INTESTINAL MOTILITY DISORDERS
维生素 A 缺乏和肠蠕动障碍
- 批准号:
8243606 - 财政年份:2010
- 资助金额:
$ 32.5万 - 项目类别:
VITAMIN A DEFICIENCY AND INTESTINAL MOTILITY DISORDERS
维生素 A 缺乏和肠蠕动障碍
- 批准号:
7861745 - 财政年份:2010
- 资助金额:
$ 32.5万 - 项目类别:
VITAMIN A DEFICIENCY AND INTESTINAL MOTILITY DISORDERS
维生素 A 缺乏和肠蠕动障碍
- 批准号:
8449206 - 财政年份:2010
- 资助金额:
$ 32.5万 - 项目类别:
相似海外基金
Development of a single-use, ready-to-use, sterile, dual chamber, dual syringe sprayable hydrogel to prevent postsurgical cardiac adhesions.
开发一次性、即用型、无菌、双室、双注射器可喷雾水凝胶,以防止术后心脏粘连。
- 批准号:
10669829 - 财政年份:2023
- 资助金额:
$ 32.5万 - 项目类别:
Novel Bioprinted Neural Stem Cell-Embedded Hydrogel Matrices for Enhanced Treatment of Glioblastoma
新型生物打印神经干细胞嵌入水凝胶基质,用于增强胶质母细胞瘤的治疗
- 批准号:
10749330 - 财政年份:2023
- 资助金额:
$ 32.5万 - 项目类别:
Nanoparticle-Enhanced Radiation Therapy for DIPG
DIPG 纳米粒子增强放射治疗
- 批准号:
10592202 - 财政年份:2023
- 资助金额:
$ 32.5万 - 项目类别:
Designing a targeted 'super adjuvant' nanoparticle platform for vaccination
设计用于疫苗接种的靶向“超级佐剂”纳米颗粒平台
- 批准号:
10647117 - 财政年份:2023
- 资助金额:
$ 32.5万 - 项目类别:
Effects of Poly(ethylene glycol) Immunogenicity on Implant Biocompatibility
聚乙二醇免疫原性对植入物生物相容性的影响
- 批准号:
10504301 - 财政年份:2022
- 资助金额:
$ 32.5万 - 项目类别:
Biodegradable, Biocompatible Pressure Sensitive Adhesives
可生物降解、生物相容性压敏粘合剂
- 批准号:
10677869 - 财政年份:2022
- 资助金额:
$ 32.5万 - 项目类别:
I-Corps: A Sprayable Tissue-Binding Hydrogel to Prevent Postsurgical Cardiac Adhesions
I-Corps:一种可喷雾的组织结合水凝胶,可防止术后心脏粘连
- 批准号:
10741261 - 财政年份:2022
- 资助金额:
$ 32.5万 - 项目类别:
Effects of Poly(ethylene glycol) Immunogenicity on Implant Biocompatibility
聚乙二醇免疫原性对植入物生物相容性的影响
- 批准号:
10697334 - 财政年份:2022
- 资助金额:
$ 32.5万 - 项目类别:
A Sprayable Tissue-Binding Hydrogel to Prevent Postsurgical Cardiac Adhesions
一种可喷雾的组织结合水凝胶,用于防止术后心脏粘连
- 批准号:
10546558 - 财政年份:2022
- 资助金额:
$ 32.5万 - 项目类别:
Effects of Poly(ethylene glycol) Immunogenicity on Implant Biocompatibility
聚乙二醇免疫原性对植入物生物相容性的影响
- 批准号:
10809875 - 财政年份:2022
- 资助金额:
$ 32.5万 - 项目类别: